4-Pro-MeT (Nysion): Scientific Guide to the Research Chemical 2026

TL;DR — 4-Pro-MeT at a Glance

4-Pro-MeT, marketed under the amama brand name Nysion, is a synthetic research chemical from the tryptamine class, discussed in the scientific community primarily as a research subject for serotonin receptor pharmacology and prodrug metabolism. The following article summarises the current state of preclinical literature, the German and European legal status, and analytical quality standards.

• Chemical classification: Synthetic tryptamine with acyl ester substitution at position 4 of the indole ring; structurally belonging to the psilocybin analog class (4-substituted tryptamines)
• Structural relationship: Close structural relationship to Psilocybin / 4-AcO-DMT and psilocin; the propionyl moiety distinguishes 4-Pro-MeT from the acetyl moiety of 4-AcO-DMT — minor modifications with potentially significant pharmacological consequences
• Legal status DE (as of May 2026): Not listed by name in the BtMG; NpSG substance-group assessment is legally unresolved and subject to case-by-case evaluation; AMG risk in the event of consumption-related advertising
• Preclinical research: Direct, peer-reviewed data on 4-Pro-MeT are considerably limited in the literature; pharmacology is hypothesized primarily from structural analogy to related 4-substituted tryptamines
• Unknown risks: As a poorly characterised substance, long-term toxicology, dose-response curves, and the interaction profile in humans are not scientifically established
• Community term "Legal Psilos": Circulates in online forums as an informal alias; amama explicitly distances itself from this framing as pharmacologically misleading
• amama position: Nysion (4-Pro-MeT) is sold exclusively as analytical reference material and research chemical for legitimate scientific, forensic, and analytical purposes — not for human consumption

What is 4-Pro-MeT?

Chemical Identity and Nomenclature

4-Pro-MeT is the common shorthand used in the research chemical community for a compound whose full systematic name is variably designated in the research literature. The name derives from the functional group at position 4 of the tryptamine scaffold: 4-propionyloxy (Pro) combined with an N-methyl-N-ethyl substitution at the terminal nitrogen (MeT — methyl/ethyl tryptamine). The name thus follows the abbreviated notation established in the RC community for structurally modified tryptamines.

A consistently used IUPAC designation for 4-Pro-MeT as a standalone compound is, at the time of writing this article (May 2026), not unambiguously documented in peer-reviewed sources. The exact structure is variably described in scene literature and on analytical data sheets, which constitutes a methodological problem for research replication. A confirmed CAS number for this specific compound is not publicly accessible to the best of current knowledge; those seeking it for analytical purposes are advised to verify reference data sheets on the basis of HPLC/MS spectra.

Structural Class and Molecular Characteristics

Structurally, 4-Pro-MeT belongs to the class of 4-substituted tryptamines — a subgroup of indolealkylamines characterised by a functional group at position 4 of the indole ring and an aliphatic amino group. The core scaffold is tryptamine (2-(1H-indol-3-yl)ethanamine), to whose indole ring a propionyloxy moiety (–O–CO–CH₂–CH₃) is attached at position 4, while a methyl and an ethyl group are present at the terminal amine.

This substitution architecture is pharmacologically significant: the ester moiety at position 4 confers potential prodrug character on the compound. In analogy to structurally related substances such as 4-AcO-DMT — whose acetyl group is hydrolysed by endogenous esterases to 4-HO-DMT (psilocin) — it is hypothesized for 4-Pro-MeT that enzymatic cleavage of the propionyl moiety could release the corresponding 4-hydroxy tryptamine metabolite. This hypothesis is based, however, on structural analogy, not on direct published metabolisation studies for 4-Pro-MeT.

Structural Relationship to Psilocybin and 4-AcO-DMT

The following schematic overview illustrates the structural relationships:

• Psilocybin: 4-phosphoryloxy-N,N-dimethyltryptamine — the phosphate ester is dephosphorylated in the organism by alkaline phosphatase to psilocin (4-HO-DMT)
• Psilocin (4-HO-DMT): The free 4-hydroxy tryptamine; considered the pharmacologically active metabolite of Psilocybin; primary 5-HT2A agonist
• 4-AcO-DMT: 4-acetoxy-N,N-dimethyltryptamine — acetyl ester; structurally close psilocin precursor; discussed in the research literature as a prodrug (cf. Nichols, 2004)
• 4-Pro-MeT: 4-propionyloxy-N-methyl-N-ethyltryptamine — propionyl ester instead of acetyl ester (longer acyl chain); N-methyl/N-ethyl instead of N,N-dimethyl — thus differing from 4-AcO-DMT in two positions

These apparently minor structural differences are pharmacologically non-trivial: even small modifications can substantially shift receptor binding affinity, lipophilicity (and thus CNS penetration), metabolisation rate, and the toxicity profile. The scientific literature on structure-activity relationships (SAR) within the tryptamine class — summarised among other sources in Shulgin's TiHKAL (1997) as well as in more recent pharmacological reviews — consistently emphasises this point.

For further structural information on related compounds, reference is made to the PubChem entries for 4-AcO-DMT (CID: 9908089), psilocin (CID: 4980), and Psilocybin (CID: 10624).

Pharmacology: What Does Preclinical Research Say?

State of the Data — An Honest Assessment

First, methodological transparency: Direct preclinical data on 4-Pro-MeT as a specific compound are considerably limited to absent in the peer-reviewed literature as of May 2026. The pharmacology discussed below is — unless expressly indicated otherwise — extrapolated from the well-documented pharmacology of structurally related compounds (in particular psilocin and 4-AcO-DMT) and classified as hypothetical for 4-Pro-MeT. This extrapolation is an established approach in early drug discovery (SAR analysis), but does not replace direct studies.

Receptor Pharmacology (Hypothetical, Based on Structural Analogy)

4-substituted tryptamines of the psilocin class are consistently described in the research literature as 5-HT2A receptor agonists. The 5-HT2A receptor — a metabotropic serotonin receptor expressed predominantly in cortical pyramidal cells — is considered the primary mechanism of action of classical serotonergic psychedelics (cf. Halberstadt & Geyer, 2011; Nichols, 2016).

For 4-Pro-MeT, on the basis of structural analogy to psilocin, it is hypothesized that after potential ester hydrolysis (prodrug activation) the released 4-hydroxy metabolite could also exhibit 5-HT2A affinity. In addition, preclinical studies discuss further serotonergic targets for this substance class:

• 5-HT2C: Frequently identified as a secondary target of classical psychedelics; modulatory role (cf. Nichols, 2016)
• 5-HT1A: Some 4-substituted tryptamines show in vitro affinity for 5-HT1A; functionally opposed to 5-HT2A (cf. Halberstadt & Geyer, 2011)
• Sigma-1 receptor and others: Further targets have been explored for structurally related tryptamines in individual studies; these data are specifically absent for 4-Pro-MeT

Important: This list describes hypothetical pharmacological targets based on structural relatedness — it is not a statement about binding affinities actually measured at 4-Pro-MeT. Radioligand binding studies or functional assays for 4-Pro-MeT are, to the knowledge of the article's authors, not available in the published literature.

Prodrug Hypothesis and Metabolism

The propionyloxy moiety at position 4 suggests — in analogy to 4-AcO-DMT — a prodrug characteristic. In preclinical studies on 4-AcO-DMT, it was discussed that serum esterases and hepatic carboxylesterases can cleave the acyl group, yielding the free 4-hydroxy tryptamine metabolite (cf. Shulgin & Shulgin, 1997; Nichols, 2004). Formally the same chemical logic applies to 4-Pro-MeT.

However: the propionyl group is longer than the acetyl group (one additional CH₂), which affects steric properties and potentially the hydrolysis kinetics. Whether and how rapidly esterases would cleave the propionyl moiety from 4-Pro-MeT is not published pharmacologically. The half-life and the CYP enzymes involved for 4-Pro-MeT itself are likewise uncharacterised.

Safety Pharmacology and Toxicological Gaps

For assessment in the research context, it is essential to note that dose-response relationships, no-observed-adverse-effect levels (NOAEL), lethal dose 50 (LD₅₀) and other toxicological parameters for 4-Pro-MeT in animal models have not been published to the best of current knowledge. This data gap is characteristic of novel research chemicals and fundamentally distinguishes 4-Pro-MeT from Psilocybin, for which extensive preclinical and initial clinical safety data are now available (cf. Johnson et al., 2008; Carhart-Harris et al., 2016).

4-Pro-MeT Compared to Psilocybin and 4-AcO-DMT

The following table serves scientific classification and is expressly not a recommendation or equivalence statement:

Critical note: Structural similarity does not imply pharmacological or toxicological identity. The research literature on tryptamine SAR repeatedly documents that minor structural modifications — altered acyl chain length, differing N-alkylation — can cause drastic changes in receptor selectivity, intrinsic activity, metabolisation rate, and toxicity profile (cf. Glennon & Dukat, 1995; Halberstadt & Geyer, 2011). Equating 4-Pro-MeT with Psilocybin or 4-AcO-DMT is not scientifically justified.

Reported Effects in Online Forums — Distanced Presentation

Methodological Caveat

Online experience reports on platforms such as Erowid.org, Reddit (r/researchchemicals, r/DesignerDrugs) and Bluelight.org constitute anecdotal self-reports without controlled conditions. They are not subject to scientific quality review; the reporting individual has generally not performed analytical verification of the consumed material; and placebo effects, contextual expectations, and potential substance misidentification cannot be methodologically excluded. amama regards these reports exclusively as sociological and pharmacovigilance data material — not as scientific evidence for effects of 4-Pro-MeT.

Descriptions Circulating in the Community

In relevant online forums, 4-Pro-MeT is subjectively described in various reports by users who claim to have consumed the material — contrary to its research-purpose labelling. Community consensus descriptions (as of research conducted in May 2026 from publicly accessible threads) include reports of a psilocybin-like subjective profile, characterised in relation to 4-AcO-DMT as "somewhat shorter in duration" or "slightly different in character." The variability of reports is considerable; consistency in the sense of a scientific effect profile cannot be derived from these sources.

Bluelight harm reduction threads on 4-substituted tryptamines regularly emphasise the risk profile of poorly researched substances: unknown purity, absence of dosage information, and the risk of serotonergic interactions are cited as central concerns.

amama Position on Forum Reports

amama evaluates these forum reports as evidence that 4-Pro-MeT is pharmacologically not inert and carries risks when used in a non-research-compliant manner, the extent of which cannot be scientifically qualified. These reports do not in any way substitute controlled toxicological or pharmacological research and are mentioned here exclusively in the interest of complete information in the spirit of scientific transparency.

Legal Status in Germany and the EU 2026

This section does not constitute legal advice. For specific legal questions, a lawyer specialising in pharmaceutical and narcotics law should be consulted.

Narcotics Act (BtMG)

The German Narcotics Act lists specific substances as well as defined stereoisomers in its Annexes I, II, and III. 4-Pro-MeT is not listed by name in any of the BtMG annexes (as of May 2026). The substance is therefore not subject to the BtMG regime, as long as no judicial subsumption under a general clause occurs — one which is currently not provided for in the BtMG for new substances of this type.

Psilocybin and psilocin, by contrast, are listed in BtMG Annex I and are therefore not marketable in Germany — neither for sale, nor for acquisition, nor for possession (except within the framework of approved research).

New Psychoactive Substances Act (NpSG)

The NpSG of July 2017 pursues a substance-group approach: rather than listing individual substances, it lists chemical substance groups under which new compounds may fall. The NpSG annex includes, among others, the group of substituted tryptamines in a formulation intended to capture structurally related compounds.

Whether 4-Pro-MeT falls under the NpSG substance-group definition for tryptamines is not conclusively resolved in law and is assessed on a case-by-case basis by public prosecutors and courts. The NpSG tryptamine group is formulated such that it can capture compounds with an indole core structure and specific N-substitutions — the precise interpretation with regard to 4-position acyl ester modifications and specific N-alkylation patterns is a matter of legal interpretation, for which no uniform case law has been published.

Practical consequence: A genuine legal uncertainty exists. An assessment that 4-Pro-MeT "clearly does not fall under the NpSG" would not be credible. At the same time, automatic subsumption is not established. This is the definition of a legal grey area.

Medicinal Products Act (AMG)

The AMG is of considerable relevance to the distribution of research chemicals: if a substance is advertised with efficacy claims for human consumption — for example with claims such as "Legal Psilos" or similar consumption-related descriptions — it may be classified as a medicinal product within the meaning of § 2 AMG (functional medicinal product). A medicinal product placed on the market without authorisation constitutes a criminal offence under § 96 AMG.

amama consistently avoids this AMG risk by labelling exclusively as a research chemical, without any consumption-related advertising.

EU Level and EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) operates an Early Warning System (EWS) for new psychoactive substances. 4-substituted tryptamines as a class are included in EMCDDA monitoring (cf. EMCDDA, 2015). Individual EU member states have regulated tryptamine derivatives at the national level; an EU-wide risk assessment specific to 4-Pro-MeT is not publicly known.

Summary of Legal Status

Why is 4-Pro-MeT Called "Legal Psilos"? — A Critical Assessment

Origin of the Term

The term "Legal Psilos" is an informal marketing concept used in the research chemical community for substances that are structurally related to Psilocybin and are not listed by name in narcotics legislation at the time of the designation. The framing is strategic: it exploits the well-known name "Psilocybin" as a reference point to generate attention and to suggest an image of safety and efficacy.

The same strategy is found in terms such as "Legal MDMA" (for cathinones or MDA analogues), "Legal Cocaine" (for certain stimulants), or "Legal Heroin" (for opiate analogues) — designations that are consistently criticised by regulatory authorities and harm reduction organisations as misleading and potentially dangerous (cf. EMCDDA, 2019).

Why the Framing is Scientifically Misleading

1. Equivalence of effects is not established: Structural similarity does not mean identical pharmacology. The subjective effect profile of Psilocybin has been scientifically characterised over decades; these data are absent for 4-Pro-MeT
2. Transfer of safety profile is impermissible: Psilocybin is considered comparatively well tolerated in controlled study settings (cf. Johnson et al., 2008). This statement does not apply to 4-Pro-MeT, whose toxicology is uncharacterised
3. "Legal" suggests freedom from risk: The legal status of a substance is not an indicator of its biological safety; many legal substances are more toxic than illegal ones
4. Risk of confusion: Users purchasing "Legal Psilos" may mistakenly receive other substances

amama Position

amama uses the term "Legal Psilos" in this article exclusively for the purpose of informative contextualisation of search terms circulating in the community. We expressly do not recommend 4-Pro-MeT (Nysion) as a substitute or equivalent to Psilocybin, psilocin, or 4-AcO-DMT — neither for human consumption nor for any other consumption-related purpose. The product is sold as a research chemical for analytical, forensic, and scientific purposes.

Known and Unknown Risks

Acute Risks (Hypothetical, Based on Substance Class Analogy)

For 4-substituted tryptamines as a class, the following acute risk profiles are discussed in the preclinical literature and forensic-toxicological case reports — these are not specifically characterised for 4-Pro-MeT, but are assessed as potentially relevant given its substance class membership:

• Serotonin syndrome: Upon combination of serotonergic substances with MAO inhibitors or other serotonergic agents — potentially life-threatening
• Cardiovascular stress: Tachycardia, blood pressure fluctuations — documented in case reports on tryptamines (cf. Gable, 2004)
• Psychological reactions: Acute anxiety states, panic attacks, disorientation — plausible from the substance class; not specifically established for 4-Pro-MeT

Chronic Risks (Largely Unknown)

For poorly characterised research chemicals, long-term toxicology data are standardly unavailable. Specifically absent for 4-Pro-MeT:

• Neurotoxicity studies
• Hepatotoxicity data
• Cardiotoxicity evaluations
• Dependence and tolerance studies

Substance Quality and Purity Risks

When acquiring research chemicals from non-certified sources, there are considerable purity risks: impurities, incorrect substance identification, and inaccurate concentration labelling are documented in the forensic literature for RC markets (cf. Brunt et al., 2017). amama addresses this risk through batch analytics (HPLC/MS standard).

Interaction Risks

Particularly critical from the risk profile of structurally related substances:

• MAO inhibitors (MAOIs): Can considerably prolong and intensify the metabolism of tryptamines — assessed as high-risk for tryptamines as a substance class
• Selective serotonin reuptake inhibitors (SSRIs): Potential interactions; serotonin syndrome risk
• Other serotonergic substances: Additive effect on serotonin transmission

Quality and Analytical Standards at amama — Nysion

amama sells 4-Pro-MeT under the brand name Nysion exclusively as a research chemical to the following standards:

• Batch identification: Each delivery unit bears a batch number used to trace the analytical certificate
• Analytical verification: Nysion batches are ideally verified for identity and purity by means of HPLC/MS analytics; corresponding certificates (CoA — Certificate of Analysis) are provided on request for research purposes
• Form of supply: Nysion is available as a solution at a defined concentration (5 mg/ml in a suitable solvent; 0.5 mg per drop in accordance with the analytical graduation) — exclusively as a reference standard for measurement applications
• Buyer requirements: Sale exclusively to persons of legal age; buyers declare upon purchase that they will use the material exclusively for legal research, analytical, or forensic purposes
• No consumption-related communication: amama does not provide any consumption-related information; enquiries concerning dosages or administration protocols will not be answered

Nysion (4-Pro-MeT) is available in the amama shop at: amama.space/products/nysion — for research purposes only.

Reference Literature

The following sources form the scientific basis of this article. Direct primary studies on 4-Pro-MeT as an individual substance are not available in the published literature; the sources cited relate to structurally related substances, the substance class, or the regulatory context.

1. Nichols, D.E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
2. Nichols, D.E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
3. Halberstadt, A.L. & Geyer, M.A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017
4. Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F.I., Bäbler, A., Vogel, H. & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 9(17), 3897–3902. https://doi.org/10.1097/00001756-199812010-00024
5. Johnson, M.W., Richards, W.A. & Griffiths, R.R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587
6. Carhart-Harris, R.L., Bolstridge, M., Rucker, J. et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366%2816%2930065-7)30065-730065-7)
7. Shulgin, A. & Shulgin, A. (1997). TiHKAL: Tryptamines I Have Known and Loved. Transform Press, Berkeley. (Reference work on the SAR of the tryptamine class; no DOI available; ISBN: 0-9630096-9-9)
8. Gable, R.S. (2004). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 99(6), 686–696. https://doi.org/10.1111/j.1360-0443.2004.00744.x
9. EMCDDA — European Monitoring Centre for Drugs and Drug Addiction (2015). New psychoactive substances in Europe: An update from the EU Early Warning System. Publications Office of the European Union, Luxembourg. https://www.emcdda.europa.eu/publications/rapid-communications/2015/new-psychoactive-substances_en
10. EMCDDA (2019). New psychoactive substances: Global markets, harms and policy responses. EMCDDA–Europol Joint Report. https://www.euda.europa.eu/
11. Brunt, T.M., Niesink, R.J.M., van den Brink, W. & van Amsterdam, J.G.C. (2017). Quality of the illicit drug supply and the composition of purchased drugs and their relationship to harm. Drug and Alcohol Dependence, 176, 107–114. https://doi.org/10.1016/j.drugalcdep.2017.03.007
12. Glennon, R.A. & Dukat, M. (1995). Serotonin receptors and their ligands: A lack of selective agents. Pharmacology Biochemistry and Behavior, 51(4), 829–836. https://www.euda.europa.eu/)00050-700050-7)
13. Federal Ministry of Health (2017). New Psychoactive Substances Act (NpSG). Federal Law Gazette I, p. 2955. Available at: https://www.bundesgesundheitsministerium.de (no DOI; statutory text)
14. Kaupmann, K. et al. and Research Services of the German Bundestag (2018). On the effects and regulation of New Psychoactive Substances (NPS) in Germany. WD 9 – 3000 – 025/18. https://www.bundestag.de/resource/blob/555824/... (Research Services opinion; no direct DOI)

FAQ — 10 Frequently Asked Questions about 4-Pro-MeT (Nysion)

1. What is 4-Pro-MeT?

4-Pro-MeT is a synthetic research chemical from the class of 4-substituted tryptamines. The compound is discussed in the scientific community as a research subject for serotonin receptor pharmacology and prodrug metabolism, and is sold under the brand name Nysion by amama.space exclusively for analytical and scientific purposes.

2. Is 4-Pro-MeT legal in Germany?

As of May 2026, 4-Pro-MeT is not listed by name in the BtMG. Whether the substance falls under the NpSG substance-group definition for tryptamines is not conclusively resolved in law and constitutes a grey area that requires individual legal case-by-case assessment. AMG risk exists in the event of advertising with consumption or efficacy claims. This statement does not constitute legal advice.

3. Is 4-Pro-MeT the same as Psilocybin or 4-AcO-DMT?

No. Although 4-Pro-MeT structurally belongs to the same substance class (4-substituted tryptamines), it differs in the type of 4-position acyl ester (propionyl rather than acetyl as in 4-AcO-DMT, or phosphate as in Psilocybin) and in the N-substitution (N-methyl/N-ethyl rather than N,N-dimethyl). According to SAR research, these differences can have considerable pharmacological consequences; equating them is not scientifically justified.

4. Why is 4-Pro-MeT referred to as "Legal Psilos"?

This term circulates in online communities as an informal alias and reflects a marketing strategy that generates attention through well-known substance names. amama regards this framing as pharmacologically misleading, as it suggests an equivalence of effects and safety that is not scientifically established. The term is used by amama exclusively for informational purposes in this article.

5. What research data exist on 4-Pro-MeT?

Direct peer-reviewed primary data on 4-Pro-MeT as an individual compound are, to the best of current knowledge (May 2026), considerably limited to absent in the published literature. Pharmacology is hypothesized primarily from the SAR literature on structurally related compounds such as psilocin and 4-AcO-DMT. This data gap is a defining characteristic of 4-Pro-MeT as a "novel" research chemical.

6. Who may purchase Nysion (4-Pro-MeT) from amama?

Nysion is sold exclusively to persons of legal age who are acquiring the material for legitimate research, analytical, or forensic purposes. By making a purchase, buyers declare that they will not use the substance for human consumption and will employ it exclusively within the framework of applicable legal provisions. amama reserves the right to decline purchases where there is reasonable suspicion of use for purposes other than those declared.

7. What is the tryptamine class?

Tryptamines are a group of organic compounds sharing the tryptamine scaffold (2-(1H-indol-3-yl)ethanamine). As a substance class they encompass endogenous neurotransmitters (serotonin, DMT in trace amounts), natural psychedelics (Psilocybin from fungi, DMT from plants), and numerous synthetic derivatives with varying pharmacology. The class is the subject of extensive basic pharmacological research, particularly with respect to serotonin receptor pharmacology.

8. How does 4-Pro-MeT differ chemically from Psilocybin and 4-AcO-DMT?

4-Pro-MeT bears a propionyloxy moiety (–O–CO–C₂H₅) at position 4 of the indole ring, whereas Psilocybin bears a phosphate ester and 4-AcO-DMT bears an acetyl ester (–O–CO–CH₃) at the same position. Additionally, 4-Pro-MeT is substituted at the terminal amine with one methyl and one ethyl group, whereas Psilocybin and 4-AcO-DMT carry two methyl groups. This combination of extended acyl chain and asymmetric N-dialkylation has not been separately pharmacologically characterised in the published literature.

9. Are there clinical studies with 4-Pro-MeT?

To the best of current knowledge (May 2026), no registered or published controlled clinical studies with 4-Pro-MeT in humans exist. This fundamentally distinguishes the substance from Psilocybin, for which Phase II and Phase III studies are now available. Researchers with an interest in this area can consult clinical trial registries (clinicaltrials.gov, EU Clinical Trials Register) to monitor whether this changes.

10. What must I observe regarding the shipping and storage of Nysion?

As a research chemical, Nysion (4-Pro-MeT) should be stored in accordance with the conditions specified on the analytical data sheet — typically cool, dry, protected from light, and out of reach of unauthorised persons. The import into other EU member states or third countries must be independently checked for legal compliance at the destination prior to shipment, as national regulations vary. Nysion may be used exclusively for the research and analytical purposes declared in the purchase agreement.

Related amama Resources and Collections

• **Research Chemicals Collection** — All analytical reference materials and research chemicals in the amama range
• **Harm Reduction & Safety Information** — General information on the risks of psychoactive substances in the spirit of harm minimisation
• **Legal Drugs in Germany 2026** — Legal status overview of regulated and unregulated psychoactive substances in Germany
• **Iboga Scientific Guide** — Example of a traditional plant-derived substance with an extensive research base, in contrast to synthetic research chemicals

Last updated: May 2026 | amama.space — Berlin Smartshop | Material for research, analytical, and forensic purposes

⚠️ For research use only, not for human consumption. This article is exclusively scientific and legal information. No application guidance. No medical advice. No encouragement to consume. In medical emergencies: Emergency 112. In cases of suspected poisoning: Poisons Centre Berlin +49 30 19240. For legal questions: a lawyer specialising in narcotics and pharmaceutical law. ⚠️

Designer Compounds at amama: Browse the Designer Compounds collection →